SOMATOTROPICS, MEMORY & AGING RESEARCH TRIAL ("SMART")

生长激素、记忆力

• 批准号: 7603491
• 负责人: MICHAEL V. VITIELLO
• 金额: $ 1.63万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7603491
• 关键词: Accounting; Age; Alzheimer' s Disease; Animals; Caregivers; Caring; Cognition; Cognitive; Computer Retrieval of Information on Scientific Projects Database; Degenerative Disorder; Dementia; Diagnosis; Elderly; Funding; Grant; Hormonal; Human; Impaired cognition; Individual; Institution; Insulin-Like Growth Factor I; Intervention; Literature; Memory; Patients; Process; Quality of life; Research; Research Personnel; Resources; Risk; Sampling; Somatotropin; Somatotropin-Releasing Hormone; Source; United States; United States National Institutes of Health; Woman; aging brain; cognitive function; cost; experience; improved; mild neurocognitive impairment; neurodegenerative dementia; older men

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The societal burden of Alzheimer's disease (AD) and other primary neurodegenerative dementias is monumental with total annual costs estimated at $100 billion (1996 dollars) per year in the United States. AD is the most common primary degenerative disorder of the aged brain, and accounts for over 50% of all cases of dementia in patients 65 years or older. The need to identify and treat individuals as early as possible in the AD process is clear, and justifies intensification of studies of individuals with Mild Cognitive Impairment (MCI) who are at risk for progression to dementia within a few years. Successful interventions to improve cognitive function and delay decline in individuals with MCI promise to forestall the severe loss of quality of life for patients and their caregivers, and to allay or reduce the growing costs of care. There is considerable and compelling evidence from both the animal and human literature that the actions of the somatotrophic hormonal axis (growth hormone releasing hormone/growth hormone/insulin-like growth factor I) have significant and predictable effects on cognitive function (memory and reasoning ability). In a preliminary study, we have shown that five months of growth hormone releasing hormone (GHRH) treatment improves cognitive function in healthy older men and women, and also have preliminary evidence that supports the likelihood of a similar effect in individuals diagnosed with MCI. GHRH may be of direct benefit to individuals who are experiencing a mild cognitive impairment and who may be at risk for continued cognitive decline. We propose to extend our initial GHRH finding, using a comprehensive cognitive assessment battery. We will extend our examination of the cognition-enhancing effects of GHRH to a sample of older adults with MCI.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 美国阿尔茨海默氏病（AD）和其他原发性神经退行性痴呆症的社会负担是巨大的，在美国，年总成本估计为每年1000亿美元（1996年）。 AD是老年大脑中最常见的原发性退行性疾病，占65岁以上患者所有痴呆症患者的50％以上。 在广告过程中，需要尽早识别和治疗个体的需求是明确的，并证明对有轻度认知障碍（MCI）的研究的加强是合理的，而这些患者（MCI）在几年内有进展到痴呆症的风险。 成功改善MCI患者认知功能和延迟下降的成功干预措施有望阻止患者及其护理人员的严重生活质量损失，并减轻或减少不断增长的护理成本。来自动物和人类文献的大量证据表明，母营养激素轴的作用（生长激素释放激素/生长激素/胰岛素样生长因子i）对认知功能（记忆和推理能力）具有显着且可预测的影响。在一项初步研究中，我们表明，五个月的生长激素释放激素（GHRH）治疗可提高健康的老年男性和女性的认知功能，并且还有初步证据，这些证据支持在诊断为MCI的人中具有相似作用的可能性。 GHRH可能会直接受益于患有轻度认知障碍并可能持续认知能力下降的人。我们建议使用全面的认知评估电池扩展最初的GHRH发现。 我们将扩展对GHRH认知增强作用的检查，以了解MCI的老年人样本。